OPINION Everything on this page was said in a consultation or call, not written in a signed document; it is the doctor's view, not an established fact. How to read the tags
Bottom line
ULIS Clinic (Zaporizhzhia) considered radiofrequency ablation (RFA) the only clearly discussable local procedure from their side, subject to an in-person ultrasound assessment of whether a safe needle trajectory exists. Electrochemotherapy was considered technically unsuitable for this liver situation. Chemoembolization was described as theoretically possible, but dependent on vascular access, angiography and availability of an appropriate vascular/interventional specialist. Yttrium-90 radioembolization was recognized as conceptually similar to embolization, but the doctor was not aware of successful routine use in Ukraine.
Speaker-Separated Summary
Explained that after about 3.5 years of inactive liver disease on imatinib, new active mural components appeared in known liver lesions. He described two active areas: a left-lobe component and a right-sided approximately 3 × 4 cm active metastasis/implant near a vein.
Reported liquid-biopsy findings with KIT exon 11 driver plus secondary exon 13 and exon 18 resistance mutations, raising concern for polyclonal imatinib resistance. He asked whether removing one progressing focus could reduce one resistance clone and allow continued imatinib.
Asked about local options: RFA/thermal ablation, electrochemotherapy, chemoembolization, and Y90/SIR-sphere radioembolization. He also raised safety concerns because the patient previously developed PRES with intracranial hemorrhage after pazopanib, thought to be related to rapid tumor breakdown, intoxication and hypertension.
Stated that electrochemotherapy is not appropriate here with the equipment known to him, because electrode penetration is only about 4-6 mm and would not treat the whole volume of a liver tumor focus.
Explained that RFA could be considered only if the ultrasound doctor can clearly visualize the target and guide a safe applicator path. CT or PET-CT helps correlate anatomy and identify the active focus, but ultrasound navigation is needed for placement.
Clarified that large vessels are usually not the main RFA obstacle because blood flow can dissipate heat, but bile ducts and safe access angles must be assessed directly. If the lesion is not visible on ultrasound, blind placement is not acceptable.
Clinical Points From the Call
| Topic | Condensed content |
|---|---|
| Needed imaging | A fresh PET-CT is preferable if available, so the ultrasound doctor can match the metabolically active lesion to the ultrasound target. |
| Biopsy and mutations | The doctor cautioned that mutations usually exist across many cells within a tumor, not neatly one mutation per lesion. If two lesions are progressing with new resistance mutations, physical destruction of progressing foci can still be rational if feasible. |
| Procedure course | RFA is usually a one-day procedure. Follow-up about one month later assesses necrosis/sclerosis and whether repeat treatment is needed. |
| Expected tissue effect | RFA heats tissue to about 60-90°C; treated tissue is effectively coagulated, then biologically evolves into necrosis and later fibrosis/scarring. Cyst formation was described as uncommon. |
| Post-procedure toxicity | Some intoxication/resorption syndrome is expected when necrotic products enter the blood. For 3-8 cm foci it is generally tolerated; fever and transient liver-enzyme changes may occur. |
| Supportive care | If needed, standard detoxification infusion therapy may include saline, glucose, polyionic solutions and rheosorbilact. Hepatoprotectors were described as having limited randomized evidence. |
| PRES concern | The doctor had not encountered arterial hypertension as a specific consequence of RFA, but the representative highlighted the patient's prior PRES/hemorrhage history after pazopanib. |
| Liver failure concern | The doctor did not expect liver failure from focal RFA, because it destroys a specific target rather than causing a systemic liver process. |
| Chemoembolization | Possible in theory, but would require vascular-surgery/interventional input, direct angiography and confirmation that the feeding vessel can be catheterized and embolized. |
| Y90 / SIR spheres | Recognized as radioembolization with yttrium-90 microspheres, conceptually similar to embolization. The doctor was not aware of successful established use in Ukraine. |
| Targeted therapy timing | Targeted therapy would ideally be paused around the procedure; the doctor suggested allowing at least one to two weeks for recovery. |
| Logistics | ULIS Clinic is in Zaporizhzhia only. If the patient is accepted after assessment, the procedure could potentially be done the same or next day. Approximate quoted cost: 76,000 UAH. |
Practical Outcome
Actionable next step: arrange an in-person ultrasound evaluation by ULIS Clinic's ultrasound-navigation doctor, using current CT/PET-CT data for correlation, to determine whether RFA applicator placement is technically safe.
Open decisions: whether the active left-lobe focus and the right-lobe active rim can be treated locally; whether vascular embolization is technically possible; how to coordinate any local procedure with ongoing or changed systemic TKI therapy given prior PRES risk.